【华创医药】凯莱英深度研究报告:小分子技术筑基,新兴业务渐入收获期

华创医药组公众...
Sep 16

根据《证券期货投资者适当性管理办法》及配套指引,本资料仅面向华创证券客户中的金融机构专业投资者,请勿对本资料进行任何形式的转发。若您不是华创证券客户中的金融机构专业投资者,请勿订阅、接收或使用本资料中的信息。本资料难以设置访问权限,若给您造成不便,敬请谅解。感谢您的理解与配合。摘要小分子技术筑基,新兴业务渐入收获期。凯莱英自1998年创立以来,依托连续性反应、生物酶催化等核心技术构建小分子CDMO...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10